Immunotherapy
Can Engineered T-Cells Be Improved to Better Recognize and Attack Neuroblastoma Cells?
T-cell therapy has seen much success in leukemia patients. Researchers now are trying to find out if T-cell therapy using the GD2 tumor antigen, which is on the surface of the neuroblastoma cancer cells, can bring about remission in solid…
Will Combining NK Cells From a Parent With a Humanized Antibody Be More Effective in Treating Neuroblastoma and Osteosarcoma?
Solving Kids’ Cancer supported this trial because researchers use a humanized monoclonal antibody known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them. The humanized monoclonal antibody may be more effective at activating the NK cells for…
Can T-Cells Be Engineered to Attack More Types of Pediatric Solid Tumors?
Researchers optimized the activity of a CAR (chimeric antigen receptor) constructed that targets GD2, an antigen on the surface of neuroblastoma to modify T cells for use in a future clinical trial. Project Title: Adoptive Cell Therapy for Adolescent/Pediatric Solid…
Can We Improve the Potency and Persistence of a Child’s T-Cells to Recognize and Kill Neuroblastoma Cells?
Solving Kids’ Cancer supported this work to develop a new and improved type of GD2-CAR T cells, and this work has advanced to a Phase I clinical trial also supported by Solving Kids’ Cancer. Project Title: Improving GD2 T-cell Immunotherapy…
Will a Vaccine Made of Stem Cells Be Effective Against a Deadly Brain Tumor in Children?
Solving Kids’ Cancer identified a novel trial using a cancer vaccine modeled after one used in adults for a deadly brain tumor called glioblastoma. As part of this trial, the vaccine will be combined with the drug imiquimod, which enhances…
Can We Train a Child’s Immune Cells to Recognize and Kill Cancer Cells?
Solving Kids’ Cancer supported this vaccine clinical trial that uses the cancer drug decitabine to help the immune cells better recognize and kill the cancer cells. Project Title: Combining Decitabine and Vaccine Therapy for Patients with Relapsed Neuroblastoma and Sarcoma…
By Engineering a Herpes Virus, Can We Target Tumor Cells?
HSV1716 (Seprehvir) is a “first in class” engineered oncolytic virus derived from the herpes simplex virus, and is designed to target and destroy cancer cells. Solving Kids’ Cancer brought this cutting-edge research to the U.S. and developed the first clinical…
Which Virus is Most Effective at Killing Cancer Cells?
Solving Kids’ Cancer developed a novel program to harness cutting-edge technology to identify more promising viruses. Project Title: Oncolytic Virus Development Program for Neuroblastoma Researcher: David Stojdl, PhD Institution: Children’s Hospital of Eastern Ontario Research Institute Study Type: Preclinical Status:…
Will a Modified Small Pox Virus Kill Cancer Cells?
Solving Kids’ Cancer initiated and funded the first trial in children using JX-594, a virus strain derived from the same vaccine used to eradicate small pox, for children with solid tumors. Project Title: Vaccinia Virus JX-594 for Relapsed/Refractory Neuroblastoma and…